Compare Stocks: ARQT, CORT, ELAN, and RDY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$26.92 +2.5%	$25.77	$16.71 ▼ $31.77	$3.30B	1.5	3.23 million shs	2.04 million shs
CORT Corcept Therapeutics	$116.10 -2.0%	$111.21	$28.66 ▼ $126.38	$12.81B	0.45	1.69 million shs	794,942 shs
ELAN Elanco Animal Health	$22.41 +0.3%	$24.04	$18.93 ▼ $27.98	$11.17B	1.68	5.15 million shs	6.45 million shs
RDY Dr. Reddy's Laboratories	$12.26 -0.3%	$12.09	$11.36 ▼ $15.67	$10.27B	0.28	2.77 million shs	3.17 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	+2.47%	+6.22%	+7.08%	-0.30%	+55.61%
CORT Corcept Therapeutics	-2.03%	+5.27%	-3.09%	+32.82%	+38.48%
ELAN Elanco Animal Health	+0.37%	+0.08%	-10.69%	-8.76%	+19.43%
RDY Dr. Reddy's Laboratories	-0.27%	+0.57%	+0.18%	-20.31%	-14.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$26.92 +2.5%	$25.77	$16.71 ▼ $31.77	$3.30B	1.5	3.23 million shs	2.04 million shs
CORT Corcept Therapeutics	$116.10 -2.0%	$111.21	$28.66 ▼ $126.38	$12.81B	0.45	1.69 million shs	794,942 shs
ELAN Elanco Animal Health	$22.41 +0.3%	$24.04	$18.93 ▼ $27.98	$11.17B	1.68	5.15 million shs	6.45 million shs
RDY Dr. Reddy's Laboratories	$12.26 -0.3%	$12.09	$11.36 ▼ $15.67	$10.27B	0.28	2.77 million shs	3.17 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	+2.47%	+6.22%	+7.08%	-0.30%	+55.61%
CORT Corcept Therapeutics	-2.03%	+5.27%	-3.09%	+32.82%	+38.48%
ELAN Elanco Animal Health	+0.37%	+0.08%	-10.69%	-8.76%	+19.43%
RDY Dr. Reddy's Laboratories	-0.27%	+0.57%	+0.18%	-20.31%	-14.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	32.14% Upside
CORT Corcept Therapeutics	2.50	Moderate Buy	$138.17	19.01% Upside
ELAN Elanco Animal Health	2.75	Moderate Buy	$29.70	32.54% Upside
RDY Dr. Reddy's Laboratories	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARQT, CORT, ELAN, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/24/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/18/2026	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$165.00
9/8/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/8/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/4/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/20/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/20/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/20/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/18/2026	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$164.00
8/6/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)

(Data available from 9/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$376.07M	9.00	N/A	N/A	$1.55 per share	17.37
CORT Corcept Therapeutics	$761.41M	16.48	$0.88 per share	131.28	$6.16 per share	18.85
ELAN Elanco Animal Health	$4.72B	2.37	$2.33 per share	9.63	$13.18 per share	1.70
RDY Dr. Reddy's Laboratories	$3.58B	2.86	$0.84 per share	14.52	$4.86 per share	2.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	128.20	23.61	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
CORT Corcept Therapeutics	$99.65M	$0.42	276.44	33.36	N/A	6.52%	8.26%	6.45%	11/4/2026 (Estimated)
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	17.37	1.59	-3.96%	8.13%	3.99%	11/6/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.44	27.87	21.51	2.56	10.15%	9.49%	6.32%	10/23/2026 (Estimated)

Latest ARQT, CORT, ELAN, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/23/2026	Q2 26/27	RDY Dr. Reddy's Laboratories	$0.0980	N/A	N/A	N/A	$843.48 million	N/A
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.49%	+6.96%	13.64%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
CORT Corcept Therapeutics	N/A	2.86	2.77
ELAN Elanco Animal Health	0.58	2.05	1.10
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
CORT Corcept Therapeutics	93.61%
ELAN Elanco Animal Health	97.48%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
CORT Corcept Therapeutics	20.70%
ELAN Elanco Animal Health	1.14%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
CORT Corcept Therapeutics	730	108.10 million	85.72 million	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.98 million	Optionable

ARQT, CORT, ELAN, and RDY Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 24 at 6:38 PM | prnewswire.com

Nykredit A S Takes Position in Dr. Reddy's Laboratories Ltd $RDY

September 23 at 3:28 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 22, 2026 | globenewswire.com

Dr Reddy's Laboratories stock gains attention on QDENGA vaccine deal

September 19, 2026 | ad-hoc-news.deA

Takeda, Dr Reddy's to launch dengue vaccine QDENGA in India by 2027

September 18, 2026 | msn.com

Takeda and Dr. Reddys Laboratories enter into exclusive collaboration to promote and distribute QDENGA in Indias pediatric and adult private market

September 18, 2026 | news.webindia123.comN

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

September 17, 2026 | reuters.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 17, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 15, 2026 | globenewswire.com

Wellington Management Group LLP Cuts Position in Dr. Reddy's Laboratories Ltd $RDY

September 12, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 8, 2026 | globenewswire.com

Nykredit A S Takes $2 Million Position in Dr. Reddy's Laboratories Ltd $RDY

September 8, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 3, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 1, 2026 | globenewswire.com

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded to Hold at Wall Street Zen

August 29, 2026 | marketbeat.com

Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Bank of America Corp DE

August 28, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

August 27, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

August 25, 2026 | globenewswire.com

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 19, 2026 | tmcnet.com

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 19, 2026 | businesswire.com

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 13, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARQT, CORT, ELAN, and RDY Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$26.92 +0.65 (+2.47%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$26.86 -0.06 (-0.20%)

As of 09/25/2026 07:30 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Corcept Therapeutics NASDAQ:CORT

$116.10 -2.41 (-2.03%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$115.84 -0.26 (-0.22%)

As of 09/25/2026 07:56 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Elanco Animal Health NYSE:ELAN

$22.41 +0.06 (+0.26%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$22.40 -0.01 (-0.04%)

As of 09/25/2026 07:33 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Dr. Reddy's Laboratories NYSE:RDY

$12.26 -0.04 (-0.31%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$12.26 -0.01 (-0.06%)

As of 09/25/2026 07:30 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARQT, CORT, ELAN, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARQT, CORT, ELAN, and RDY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARQT, CORT, ELAN, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARQT, CORT, ELAN, and RDY Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARQT, CORT, ELAN, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARQT, CORT, ELAN, and RDY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARQT, CORT, ELAN, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARQT, CORT, ELAN, and RDY Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Corcept Therapeutics NASDAQ:CORT

Elanco Animal Health NYSE:ELAN

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools